Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Britain Courts Anthropic Amid US Defense Department Dispute 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
JERSEY, Channel Islands, Nov. 15, 2016 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chairman and Chief Executive Officer, Paul Cowan, will present at the Jefferies 2016 London Healthcare Conference in London, UK on Thursday, November 17 at 4.00 p.m. GMT (11.00 a.m. Eastern Time).
A live audio webcast of the presentation will be available online from the investor relations page of the Company’s corporate website at www.quotientbd.com. A webcast replay will be archived on the website for approximately 45 days.
About Quotient Limited
Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQTM technology platform to offer a breadth of tests that is unmatched by existing commercially available transfusion diagnostic instrument platforms. The company’s operations are based in Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania.
Contact: Paul Cowan, Chairman & Chief Executive Officer – [email protected]; 215-497-7006
